Arsenic trioxide and the phosphoinositide 3-kinase/Akt pathway in chronic lymphocytic leukemia

Dennis J. Goussetis, Leonidas C. Platanias

Research output: Contribution to journalComment/debatepeer-review

15 Scopus citations

Abstract

Simultaneous targeting of the phosphoinositide 3-kinase (PI3K)/Akt pathway increases arsenic trioxide (ATO) - dependent cytotoxicity of chronic lymphocytic leukemia (CLL) cells, whereas it has no significant effects on normal lymphocytes. Combinations of ATO with small molecules that target PI3K and/or Akt may provide a novel approach for the treatment of CLL. Clin Cancer Res; 16(17); 4311-2.

Original languageEnglish (US)
Pages (from-to)4311-4312
Number of pages2
JournalClinical Cancer Research
Volume16
Issue number17
DOIs
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Arsenic trioxide and the phosphoinositide 3-kinase/Akt pathway in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this